Peptides for Traumatic Brain Injury — Evidence-Based Overview

How peptide Targets Peptides for Traumatic Brain Injury

Traumatic brain injury (TBI) triggers a complex cascade of pathological events that extend well beyond the initial mechanical damage. The primary injury — shearing of axons, contusion of brain tissue, disruption of the blood-brain barrier — is followed by secondary injury mechanisms including excitotoxicity from glutamate release, mitochondrial dysfunction, neuroinflammation driven by activated microglia and astrocytes, oxidative stress, and progressive neuronal apoptosis. These secondary processes can continue for days to weeks after the initial trauma and represent the window where pharmacological intervention may have the greatest impact. Peptides that target neuroprotection, neuroinflammation, neurotrophic factor modulation, and synaptic repair are of particular interest in TBI research.

Cerebrolysin is the most clinically studied peptide-based intervention for TBI. This porcine brain-derived peptide mixture contains neurotrophic factors and active peptide fragments that mimic the activity of BDNF, GDNF, NGF, and CNTF. Multiple randomized controlled trials — including studies with several hundred patients — have evaluated cerebrolysin in moderate-to-severe TBI. Results show improvements in cognitive outcomes, Glasgow Outcome Scale scores, and biomarkers of neuronal injury, though effect sizes vary across trials and some studies have methodological limitations. Cerebrolysin is approved for TBI treatment in several countries but not in the United States. Its mechanism involves promoting neuronal survival, enhancing synaptic plasticity, reducing excitotoxic damage, and modulating neuroinflammation. Semax, a synthetic analogue of ACTH(4-10), has been studied primarily in Russian clinical settings for stroke and TBI. It increases BDNF and NGF expression, modulates inflammatory cytokine profiles in the brain, and has demonstrated neuroprotective effects in cerebral ischemia models. Russian clinical data suggest cognitive improvements in TBI patients, though these studies generally do not meet Western regulatory standards for trial design and reporting. Selank, a synthetic analogue of tuftsin, provides anxiolytic and nootropic effects that may address the anxiety, cognitive impairment, and emotional dysregulation common after TBI. Its mechanisms include modulation of GABAergic transmission and inflammatory cytokine profiles.

BPC-157 has demonstrated neuroprotective properties in preclinical models including traumatic brain injury in rodents, where it reduced brain edema, improved neurological deficit scores, and modulated dopaminergic and serotonergic systems. Its effects on the nitric oxide system and growth factor modulation are potentially relevant to TBI pathophysiology, though clinical translation remains unestablished. Dihexa, a hexapeptide analogue of angiotensin IV, has shown remarkable potency in enhancing hepatocyte growth factor (HGF) signaling — approximately seven orders of magnitude more potent than BDNF at promoting synaptic connectivity in preclinical models. HGF/c-Met signaling is involved in neuronal survival and synaptic repair after brain injury. However, dihexa research is extremely early-stage with only a handful of preclinical publications, and long-term safety data is essentially nonexistent. Pinealon is a short peptide (Glu-Asp-Arg) that has shown neuroprotective effects in cell culture and animal models, potentially through regulation of gene expression in neurons and modulation of apoptotic pathways. Its evidence base is limited primarily to Russian research groups. The honest assessment is that cerebrolysin has meaningful clinical evidence for TBI, semax has moderate evidence primarily from Russian clinical practice, and the remaining peptides have preclinical rationale but lack human TBI trial data.